KTRA vs. OGEN, XBIO, HOTH, ADIL, YMTX, LIXT, ADXS, TFFP, ENVB, and SONN
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Oragenics (OGEN), Xenetic Biosciences (XBIO), Hoth Therapeutics (HOTH), Adial Pharmaceuticals (ADIL), Yumanity Therapeutics (YMTX), Lixte Biotechnology (LIXT), Ayala Pharmaceuticals (ADXS), TFF Pharmaceuticals (TFFP), Enveric Biosciences (ENVB), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical preparations" industry.
Oragenics (NYSE:OGEN) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
Oragenics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
Kintara Therapeutics received 16 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 88.89% of users gave Kintara Therapeutics an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
18.7% of Oragenics shares are owned by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are owned by institutional investors. 24.6% of Oragenics shares are owned by company insiders. Comparatively, 4.3% of Kintara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Oragenics had 4 more articles in the media than Kintara Therapeutics. MarketBeat recorded 6 mentions for Oragenics and 2 mentions for Kintara Therapeutics. Oragenics' average media sentiment score of 0.46 beat Kintara Therapeutics' score of 0.23 indicating that Kintara Therapeutics is being referred to more favorably in the news media.
Oragenics' return on equity of 0.00% beat Kintara Therapeutics' return on equity.
Kintara Therapeutics has lower revenue, but higher earnings than Oragenics. Oragenics is trading at a lower price-to-earnings ratio than Kintara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Kintara Therapeutics beats Oragenics on 10 of the 14 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
